NCT04603872View on ClinicalTrials.gov

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2026

Conditions
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryAcute Lymphoblastic Leukemia, in RelapseAcute Lymphocytic Leukaemia RefractoryNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Interventions
DRUG

CD19/BCMA Targeted CAR T-cells and dasatinib

Each subject receive CS1 Targeted CAR T-cells by intravenous infusion, and the dasatinib was combined according to the presumed regimens.

DRUG

CD19/BCMA Targeted CAR T-cells

Each subject receive CS1 Targeted CAR T-cells by intravenous infusion.

Trial Locations (1)

310003

RECRUITING

The First Hospital of Zhejiang Medical Colleage Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER